EnglishПовреждение гематоэнцефалического барьера при острых и хронических цереброваскулярных заболеваниях
И. Ианг, Г.А. Розенберг
"Библиотеке Врача"
Литература
1. Iadecola C., Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007;10:1369–1376.
2. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173–185.
3. Milner R., Hung S., Wang X., Berg G.I., Spatz M., del Zoppo G.J. Responses of endothelial cell and astrocyte matrix-integrin receptors to ischemia mimic those observed in the neurovascular unit. Stroke. 2008;39:191–197.
4. Dore-Duffy P. Pericytes: Pluripotent cells of the blood brain barrier. Curr Pharm Des. 2008;14:1581–1593.
5. Daneman R., Zhou L., Kebede A.A., Barres B.A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468:562–566.
6. Bell R.D., Winkler E.A., Sagare A.P., Singh I., LaRue B., Deane R., Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409–427.
7. Candelario-Jalil E., Gonzґalez-Falcґon A., Garcнa-Cabrera M., Leґon O.S., Fiebich B.L. Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem. 2007;100:1108–1120.
8. Tsuji K., Aoki T., Tejima E., Arai K., Lee S.R., Atochin D.N., et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005;36: 1954–1959.
9. Lapchak P.A., Chapman D.F., Zivin J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034–3040.
10. Wang X., Lee S.R., Arai K., Lee S.R., Tsuji K., Rebeck G.W., et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313–1317.
11. Yepes M., Sandkvist M., Moore E.G., Bugge T.H., Strickland D.K., Lawrence D.A. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112:1533–1540.
12. Zador Z., Bloch O., Yao X., Manley G.T. Aquaporins: Role in cerebral edema and brain water balance. Prog Brain Res. 2007;161:185–194.
13. Kim G.W., Gasche Y., Grzeschik S., Copin J.C., Maier C.M., Chan P.H. Neurodegeneration in striatum induced by the mitochondrial toxin 3-nitropropionic acid: Role of matrix metalloproteinase-9 in early blood-brain barrier disruption? J Neurosci. 2003;23:8733–8742.
14. Kim H.Y., Singhal A.B., Lo E.H. Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol. 2005;57:571–575.
15. Liu W., Hendren J., Qin X.J., Liu K.J. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke. 2009;40:2526–2531.
16. Henning E.C., Latour L.L., Warach S. Verification of enhancement of the CSF space, not parenchyma, in acute stroke patients with early blood-brain barrier disruption. J Cereb Blood Flow Metab. 2008;28:882–886.
17. Brott T., Broderick J., Kothari R., Barsan W., Tomsick T., Sauerbeck L., et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1–5.
18. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–2137.
19. Montaner J., Alvarez-Sabin J., Molina C.A., Angles A., Abilleira S., Arenillas J., et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32:2762–2767.
20. Skoog I., Wallin A., Fredman P., Hesse C., Aevarsson O., Karlsson I., et al. A population study on blood-brain barrier function in 85-yearolds: Relation to Alzheimer’s disease and vascular dementia. Neurology. 1998;50:966–971.
21. Ewing J.R., Knight R.A., Nagaraja T.N., Yee J.S., Nagesh V., Whitton P.A., et al. Patlak plots of Gd-DTPA MRI data yield bloodbrain transfer con- stants concordant with those of 14C-sucrose in areas of blood-brain opening. Magn Reson Med. 2003;50: 283–292.
22. Taheri S., Gasparovic C., Huisa B.N., Adair J.C., Edmonds C., Prestopnik J., Grossetete M., Shah N.J., Wills J., Qualls C., Rosenberg G.A. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke. 2011 (in press).
23. Marstrand J.R., Garde E., Rostrup E., Ring P., Rosenbaum S., Mortensen E.L., et al. Cerebral perfusion and cerebrovascular reactivity are reduced in white matter hyperintensities. Stroke. 2002;33:972–976.
24. Topakian R., Barrick T.R., Howe F.A., Markus H.S. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry. 2010;81:192–197.
25. Wardlaw J.M., Doubal F., Armitage P., Chappell F., Carpenter T., Munooz Maniega S., et al. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann Neurol. 2009;65:194–202.
26. De Reuck J., Crevits L., De Coster W., Sieben G., vander Eecken H. Pathogenesis of Binswanger chronic progressive subcortical encephalopathy. Neurology. 1980;30:920–928.
27. De Groot J.C., De Leeuw F.E., Oudkerk M., Van Gijn J., Hofman A., Jolles J., et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol. 2002;52:335–341.
28. Schmidt R., Scheltens P., Erkinjuntti T., Pantoni L., Markus H.S., Wallin A., et al. White matter lesion progression: A surrogate endpoint for trials in cerebral small-vessel disease. Neurology. 2004;63: 139–144.
29. Fernando M.S., Simpson J.E., Matthews F., Brayne C., Lewis C.E., Barber R., et al. White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury. Stroke. 2006;37:1391–1398.
30. Vermeer S.E., Longstreth W.T.Jr, Koudstaal P.J. Silent brain infarcts: A systematic review. Lancet Neurol. 2007;6:611–619.
31. Akiguchi I., Tomimoto H., Suenaga T., Wakita H., Budka H. Blood-brain barrier dysfunction in Binswanger’s disease; an immunohistochemical study. Acta Neuropathologica. 1998; 95:78–84.
32. Rosenberg G.A., Sullivan N., Esiri M.M. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke. 2001;32:1162–1168.
33. Nakaji K., Ihara M., Takahashi C., Itohara S., Noda M., Takahashi R., et al. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke. 2006;37:2816–2823.
34. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8:205–216.
35. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009;158:983–994.
36. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science. 2002;295:2387–2392.
37. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6:480–498.
38. Matsukawa N., Yasuhara T., Hara K., Xu L., Maki M., Yu G., et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci. 2009;10:126.
39. Zabad R.K., Metz L.M., Todoruk T.R., Zhang Y., Mitchell J.R., Yeung M., et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: A pilot study. Mult Scler. 2007;13:517–526.
40. Snapyan M., Lemasson M., Brill M.S., Blais M., Massouh M., Ninkovic J., et al. Vasculature guides migrating neuronal precursors in the adult mammalian forebrain via brainderived neurotrophic factor signaling. J Neurosci. 2009; 29:4172–4188.
41. Hermann D.M., Zechariah A. Implications of vascular endothelial growth factor for postischemic neurovascular remodeling. J Cereb Blood Flow Metab. 2009;29:1620–1643.
42. Lee S.R., Kim H.Y., Rogowska J., Zhao B.Q., Bhide P., Parent J.M., et al. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci. 2006;26:3491–3495.
43. Zhao B.Q., Wang S., Kim H.Y., Storrie H., Rosen B.R., Mooney D.J., et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441–445.
Похожие статьи
